Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

This study tests a combination of two drugs — ruxolitinib (a JAK inhibitor) and enzalutamide (a hormone therapy) — for men with metastatic castration-resistant prostate cancer (mCRPC). Ruxolitinib is typically used for blood disorders, and researchers are exploring whether it can help overcome resistance to enzalutamide in prostate cancer. **You may be eligible if...** - You are a man 18 years old or older - You have been diagnosed with progressive metastatic castration-resistant prostate cancer, confirmed as adenocarcinoma - Your cancer has progressed despite standard hormone therapy - You are in adequate physical health with acceptable blood counts and organ function **You may NOT be eligible if...** - You have had prior treatment with enzalutamide or abiraterone - You have received more than one prior chemotherapy regimen for prostate cancer - You have active or chronic infections (including HIV or hepatitis B/C) - You are on strong blood-thinning medications with active bleeding Talk to your doctor to see if this trial is right for you.